U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07018349) titled 'Low Dose Oral Minoxdil in Androgenic Alopecia' on June 01.
Brief Summary: In order to successfully treat androgenetic alopecia (AGA), this study compares the efficacy of low-dose oral minoxidil dosages of 0.25 mg and 1 mg. It addresses a critical gap in current research, as few studies have examined the relationship between low dosage and outcomes like hair diameter, density, patient satisfaction, and adverse effects, including hypertrichosis. Previous research suggests that low dose of oral minoxidil is a safe and well-tolerated option for hair loss, but the optimal dose for maximizing benefits while minimizing side effects remains...